Muhammet ÇALIK, İlknur ÇALIK, Betül GÜNDOĞDU, Sare ŞİPAL

Meme Karsinomunda VEGF ve CD44 Ekspresyonunun Aksiller Lenf Nodu Metastazına Etkisi

Amaç: Bu çalışmada, CD44 ve VEGF ekspresyonunun meme karsinomunda önemli prognostik faktörlerinden biri olan aksiller lenf nodu metastazı ile ilişkisinin araştırılması amaçlanmıştır. Gereç ve Yöntem: Bu retrospektif çalışmaya, Atatürk Üniversitesi Tıp Fakültesi (FÜTF) Patoloji Anabilim Dalı'nda 1990-2000 yılları arasında modifiye radikal mastektomi ve aksiller lenf nodu diseksiyonu yapılan 62 invaziv meme karsinomu hastası dahil edildi. Bu hastalara ait patolojik örnekler meme karsinomunun prognostik faktörleri açısından değerlendirildi. Daha sonra tümör hücrelerinde CD44 ve VEGF ekspresyonunu belirle- mek için streptavidin-biotin peroksidaz yöntemi uygulanarak immunohistokimyasal boyama yapıldı. Bulgular: Hastaların ortalama yaşı 50.7±10.66 olarak belirlendi. Olguların 17’sinde (%27.4) lenf nodu metastazı saptanmadı. Lenf nodu tutulumu olan 45 hastanın 21’inde (%33.9) 1-3 metastaz, 24’ünde ise (%38.7) 4-9 metastaz vardı. Yaş, makroskopik tümör çapı, lenfovasküler invazyon ve inflamatuvar reaksiyon gibi bazı klasik prognostik faktörler ile CD44 ve VEGF ekspresyonu arasında anlamlı korelasyon yoktu. Bununla birlikte, lenf nodu metastazı ile CD44 ve VEGF ekspresyonu istatistiksel olarak ilişkili bulunmuştur (sırasıyla, Anova p

The Effect of VEGF and CD44 Expressions on Axillary Lymph Node Metastasis in Breast Carcinom

Objective: In this study, it was aimed to investigate the relationship of CD44 and VEGF expression to axillary lymph node metastasis that is one of the most important prognostic factors in invasive breast carcinoma. Material and Method: This retrospective study included 62 invasive breast carcinoma patients who underwent modified radical mastectomy and axillary lymph node dissection between 1990-2000 in Atatürk University Faculty of Medicine (FUTF) Department of Pathology. The pathological specimens of this patients were evaluated in terms of classical prognostic factors of breast cancer. Afterwards, immunohistochemical staining was performed using the streptavidin-biotin peroxidase method to determine CD44 and VEGF expression in tumor cells. Results: The mean age at the time of diagnosis was 50.22±11.57 years for patients. Seventeen of the cases (32.2%) had no lymph node metastasis. Twenty-one (33.9%) of 42 patients with lymph node involvement had 1 to 3 metastases and 24 (38.7%) had 4 to 9 metastases. There was no signifi- cant correlation between CD44 and VEGF expression and some classical prognostic factors such as age, macroscopic tumor diameter, lymphovascu- lar invasion, and inflammatory reaction. However, lymph node metastasis and CD44 and VEGF expression were found to be statistically related (Anova p

PDF

___

1. Berner HS, Suo Z, Risberg B et al. Clinicopatho- logical assosiations of CD44 mRNA and protein expression in primary breast carcinomas. Histo- pathology 2003; 42: 546-54.
2. Seemayer CA, Breuer E, Kroll G et al. Incidance and tumour stages of the braest cancer in the re- gion of Aachen, Germany. Eur J Cancer Care 2002; 11: 16-24.
3. Rosai J. Breast. in: Rosai and Ackerman’s Surgical Pathology. Ninth Edition, London: Elsevier İnc 2004: 1763-76.
4. İrgil E: Meme kanseri epidemiyolojisi. İçinde: Ünal G, Ünal H (Editörler). Meme Hastalıkları. İs- tanbul: Nobel Tıp Kitabevleri Ltd 2001: 227-33.
5. Üskent N. Meme kanserinin doğal seyri, gelişimi, risk faktörleri dünyadaki dağlımı ve epidemiyolo- jisi. İçinde: Olgular Işığında Meme Kanseri. İzmir. Turgut Yayıncılık ve Tic. A.Ş 2003: 1-15.
6. Jemal A, Murray T, Ward E et al. Cancer Statistics 2005. CA Cancer J Clin 2005; 55: 259.
7. Özmen V, Fidaner C, Aksaz E et al. Türkiye’de meme kanseri erken tanı ve tarama programlarının hazırlanması “Sağlık Bakanlığı meme kanseri er- ken tanı ve tarama alt kurulu raporu”. Meme Sağ- lığı Dergisi 2009; 5: 125-34.
8. Fentiman IS. Fixed and modifiable risk factors for breast cancer. Int J Clin Pract 2001: 55; 527-30.
9. Weidner N. Breast. In: Weidner N, Cote RJ, Suster S, Weiss LM (Editors). Modern Surgical Patho- logy. First Edition, Philadelphia: Elsevier 2003: 539-628.
10. Sinn HP, Heider KH, Skroch-Angel P et al. Hu- man mammary carcinomas Express homo logues of rat metastasis-associated variants of CD44. Bre- ast Cancer Res Treat 1995: 36; 307-13.
11. Bankfalvi A, Terpe HJ, Breulelmann D et al. Gains and losses of CD44 expression during breast carci- nogenesis and tumour progression. Histopathology 1998: 33;107-16.
12. Tse GMK, Tan PH, Ma TKF et al. CD44 is useful in the differantiation of benign and malignant pa- pillary lesions of the breast. J Clin Pathol 2005: 58; 1185-8.
13. Price EA, Coombe DR, Murray JC. Endothelial CD44 mediates adhesion of a melanoma cell line a quiescent human endothelial cells in vitro. Int J Cancer 1996: 65; 513-8.
14. Ruiz P, Schwarzler C, Gunthert U. CD44 isoforms during differantiation and development. BioEssays 1994: 17; 17-24.
15. Haynes BF, Liao HX, Patton KL. The transmemb- rane hyalunirate receptor (CD44): multiple functi- ons, multipl forms. Cancer Cells 1991: 3; 347-50.
16. Gunthert U: CD44: a multitude of isoforms with diverse functions. Curr Top Microbiol Immunol 1993: 184; 47-63.
17. Jansen RHL, Joosten ASR, Arends JW et al. CD44v6 is not a prognostic factors in a primary breast cancer. Ann Oncol 1998: 9; 109-11.
18. Gasparini G: Prognostic value of vascular endothe- lial growth factor in breast cancer. Oncologist 2000: 5; 37-44.
19. Jacqueline A, Pauline JC, Downey S et al. Vascu- lar endothelial growth factor (VEGF) in breast cancer comparisson of plasma, serum and tissue VEGF and microvessel densitiy and effects of ta- moxifen. Cancer Res 2000: 60; 2898-905.
20. Ersöz ŞA: Meme karsinomlarında anjiogenezin histopatolojik veriler ile karşılaştırılması. Karade- niz Teknik Üniversitesi Tıp Fakültesi Patoloji AD. Uzmanlık Tezi. Trabzon 2002.
21. Risau W. Mechanisms of anjiogenesis. Nature 1997: 386; 671-4.
22. Urru SAM, Gallus S, Bosetti C et al. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients. BMC Cancer 2018; 18: 56.
23. Sengal AT, Haj-Mukhtar NS, Elhaj AM, Bedri S, Kantelhardt EJ, Mohamedani AA. Immunohistoc- hemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based ca- se series. BMC Cancer 2017; 17: 804.
24. Luo A, Wu F, Han R et al. Clinicopathological features and prognostic evaluation of bone metas- tasis in triple-negative breast cancer. J Cancer Res Ther 2017; 13: 778-84.
25. Peiris H, Mudduwa L, Thalagala N, Jayatialake K. The value of Nottingham grade in breast cancer re- visited in the Sri Lankan setting. Malays J Pathol 2017; 39: 141-8.
26. Freitas R Júnior, Nunes RD, Martins E et al. Prog- nostic factors and overall survival of breast cancer in the city of Goiania, Brazil: a population-based study. Rev Col Bras Cir 2017; 44: 435-43.
27. Kondov B, Isijanovska R, Milenkovikj Z et al. Impact of size of the tumour, persistence of estro- gen receptors, progesterone receptors, HER2Neu receptors and Ki67 values on positivity of axillary lymph nodes in patients with early breast cancer with clinically negative axillary examination. Open Access Maced J Med Sci 2017; 5: 825-30.
28. Senbanjo LT, Chellaiah MA. CD44: A multifunc- tional cell surface adhesion receptor ıs a regulator of progression and metastasis of cancer cells. Front Cell Dev Biol 2017; 5: 18.
29. Lopez JI, Camenisch TD, Stevens MV et al. CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res 2005; 65: 6755-63.
30. Franchi A, Moroni M, Paglierani M, santucci M: Expression oc CD44 standart and variant isoforms in parotid gland and parotid gland tumours. J Oral Pathol Med 2001; 30: 564-8.
31. Hosford S, Elliott J, Ma ZW et al. CD44 expres- sion in papillary serous endometrial carcinoma. Int J Gynecol Cancer 2003; 13: 480-4.
32. Sanmartín E, Ortiz-Martínez F, Pomares-Navarro E et al. CD44 induces FOXP3 expression and is related with favorable outcome in breast carcino- ma. Virchows Arch 2017; 470: 81-90.
33. Sun H, Liu T, Zhu D et al. HnRNPM and CD44s expression affects tumor aggressiveness and pre- dicts poor prognosis in breast cancer with axillary lymph node metastases. Genes Chromosomes Cancer 2017; 56: 598-607.
34. Qiu Y, Pu T, Guo P et al. ALDH(+)/CD44(+) cells in breast cancer are associated with worse progno- sis and poor clinical outcome. Exp Mol Pathol 2016; 100:145-50.
35. Oliveira RV, Souza VB, Souza PC et al. Detection of Putative Stem-cell Markers in Invasive Ductal Carcinoma of the Breast by Immunohistoche- mistry: Does It Improve Prognostic/Predictive As- sessments? Appl Immunohistochem Mol Morphol 2018; 26: 760-8.
36. Jiang W, Li Y, Ou J et al. Expression analysis of E-cad and vascular endothelial growth factor in triple-negative breast cancer patients of different ethnic groups in western China. Medicine (Balti- more) 2017; 96: 42.
37. Wang Q, Sun L, Yan J, Wang S, Zhang J, Zheng X. Expression of vascular endothelial growth fac- tor and caspase-3 in mucinous breast carcinoma and infiltrating ductal carcinoma-not otherwise specified, and the correlation with disease-free survival. Oncol Lett 2017; 14: 4890-6.
38. Yang W, Klos K, Yang Y et al. Erb B2 ove- rexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer 2002; 94: 2855- 61.
39. Skobe M, Hawighorst T, Jackson DG et al. Induc- tion of lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature Medicine 2001; 7: 192-8.
40. Gasparini G: Prognostic value of vascular endothe- lial growth factor in breast cancer. Oncologist 2000: 5; 37-44.
41. Kitadai Y, Amioka T, Haruma K et al. Clinicopat- hological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int J Cancer 2001: 93: 662-6.
42. Guang-Wu H, Sunagawa M, Jie-En L et al. The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal car- cinoma. Laryngoscope 2000; 110: 2066-9.
43. Jiang JB, Li XM, Zhang WD et al. Relationship of vascular endothelial growth factor-C and lymphangiogenesis with devalopment and progno- sis of colon cancer. Cancer 2005; 8: 516-9.
44. Choi WL, Lewis MM, Lawson D et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic pa- rameters and VEGF-family gene expression. Mo- dern Pathology 2005; 18: 143-52.
45. Linderholm B, Lindahl T, Holmberg L et al. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res 2001; 61: 2256- 60.
46. Linderholm B, Grankvist K, Wilking N et al. Cor- relation of vascular endothelial growth factor con- tent with recurrences survival and first relaps site in primary node positive breast carcinoma after ad- juvant treatment. J Clin Oncol 2000; 18: 1423-31.
47. Tsutsui S, Yasuda K, Suzuki K et al. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 2005; 14: 425-31.
48. Mattila MM, Ruohola JK, Karpanen T et al. VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int J Cancer 2002; 98: 946-51.
49. Stacker SA, Caesar C, Baldwin ME et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001; 7: 186-91.